Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Circulation. 2014 Oct 2;130(20):1772–1774. doi: 10.1161/CIRCULATIONAHA.114.012884

High Prevalence but Uncertain Clinical Significance of Orthostatic Hypotension without Symptoms

Edgar R Miller III 1,2,3, Lawrence J Appel 1,2,3
PMCID: PMC4888076  NIHMSID: NIHMS782415  PMID: 25278100

Orthostatic hypotension (OH) is common in adults, and when accompanied by symptoms (dizziness, light-headedness, or fainting) carries an increased risk of falls, fractures, and mortality.1 Symptoms are attributed to transiently reduced cerebral perfusion. The underlying causes of OH are numerous and include dehydration, “autonomic dysfunction”, and medications that affect vascular compliance or responsiveness to autonomic reflexes.2 Risk factors for OH in population-based studies include age, hypertension, hypertension treatment, diabetes, and sedative/hypnotic medication use.3

In order to standardize the assessment and diagnosis of OH, the American Autonomic Society and American Association of Neurology defines OH as a decrease in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg within 3 minutes of standing.2 Recently, the availability of continuous BP monitoring during provocative testing (going from seated to standing) has provided opportunities to further characterize patterns of OH which may have prognostic value and/or pathophysiologic relevance. While there is now a consensus on the definitions of OH and its variants, few studies have assessed the prevalence of OH and its variants in the general population. This lack of data likely reflects the absence of a simple assessment tool, which is necessary in population-based studies.

In this issue of Circulation, Finucane and colleagues present results of a population-based, nationally representative survey on the prevalence of OH in adults in Ireland.4 The investigators use a novel continuous monitor (Finometer) for waveform analysis of beat-to beat BP measurements during provocative testing. For this test, participants were supine for 10 minutes, at which time they stood for 2 minutes while the monitor recorded BP continuously. At two minutes, participants were also asked to report symptoms of “orthostatic intolerance”. In this paper, OH was defined as a decrease in systolic BP of ≥20 mm Hg or diastolic BP of ≥10 mmHg at 2 minutes of standing, in contrast to the standard 3 minute test. The authors also report two variants of OH. The variant, initial orthostatic hypotension (IOH), was defined as a drop in systolic BP of ≥ 40 mmHg or diastolic BP of ≥20 mmHg within 15 seconds of standing accompanied by symptoms (e.g. dizziness or light-headedness). The variant, impaired blood pressure stabilization, was based on the time-course of BP monitoring and was defined by a lack of returning to baseline BP after 40 seconds.5

The table summarizes principal findings of the survey. With increasing decade of life, the prevalence of OH increased as well, from 4.2% in 50–59 year olds to 18.5% in those ≥80 years. IOH was highly prevalent (~35%) and did not vary by age. The prevalence of impaired blood pressure stabilization, defined as a lack of return to baseline BP at 40 seconds upon standing, increased with each decade, and affected > 40% of those ≥ 80 years.

The relevance of these findings to clinical management of patients with OH is uncertain, given the lack of prospective data on outcomes and the overriding clinical importance of whether or not there were concurrent symptoms. It is well-recognized that most patients with OH are asymptomatic.6 Typically, reports of OH symptoms (e.g. mild and fleeting light-headedness, feeling dizziness or felling faint, or after a report of syncope) will prompt a clinical evaluation. OH associated with orthostatic symptoms is most relevant to initiating further diagnostic evaluations and in making treatment decisions. However, there are no guidelines on clinical decision-making in those with OH but without symptoms.

Measurement of OH in asymptomatic patients is presumably done for the purposed of identifying persons who are at high risk for falling. However, the relationship of OH with subsequent falls has been inconsistent in observational studies.7,8 In a large cohort of community-dwelling adults in Boston, OH was not associated with a greater risk of falls overall, except in a subgroup of those with uncontrolled hypertension. Poor vision, balance and gait problems, vertigo, muscle atrophy, co-morbid conditions, and medication use might be more important risk factors for falls than OH.

Identification of OH in patients who are symptom free may create diagnostic and therapeutic dilemmas. Detection of OH in the clinic with the continuous monitoring device would add much data, but would further complicate BP management. For example, a clinician may be reluctant to escalate antihypertensive drug treatment in an asymptomatic patient with OH, even if the patient has not achieved BP control. Large epidemiological studies have shown that anti-hypertensive medications are associated with increased risk of serious fall injuries, and some question the value of aggressive blood pressure lowering in the elderly.9 The high prevalence of OH in the elderly and perceived risk of falls led, in part, to the new JNC VIII recommendation which raised the systolic BP treatment threshold from <140 mmHg to < 150 mmHg.10 On the other hand, there is substantial concern that the new JNC VIII recommendation might increase the risk of stroke.11 Further, there is much debate on whether withdrawing antihypertensive medications on the basis of OH is justified, especially in the absence of symptoms.12

Trials of aggressive vs standard BP goals provide some reassurance that lower BP, while increasing OH symptoms, does not increase risk of falls or fractures. In the ACCORD trial, a large randomized trial of intensive goal (systolic BP < 120 mmHg) vs standard BP goal (systolic BP < 140 mmHg) in patients with Type 2 diabetes, the intensive BP goal was not associated with an increased risk of falls or fractures at one year follow-up.13 In the SANDS trial,14 there were greater reports of dizziness (35 vs 17%), but not falls, in the aggressive compared to the standard BP goal groups. In the SPS3 trial, which randomized adults following lacunar infarction, a lower BP target was associated with a trend towards an increased risk of orthostatic syncope, but a lower trend for recurrent stroke.15 For milder symptoms such as dizziness, which can often be managed by behavior modification, e.g. sitting on the side of the bed before standing, the risk of falling in those with OH may be far less than the risk of a CVD event that may occur after stopping antihypertensive therapy or liberalizing BP treatment goals.

A critical factor in decision-making on medication titration is patient preference. In a cross-sectional survey of cognitively intact adults with hypertension who were at risk for falls, 50% reported a preference for maintaining better BP control, with the potential of reducing CVD risk, while the other 50% had a preference for reducing OH symptoms from a lower dose or withdrawal of medication.16 The percentage of participants who prioritized CVD risk reduction was less in those with lower education, lower income, and those in poorer health.

The study Finucane et al. has several limitations that should be considered. First, it was a cross sectional study. Establishing the relationship of OH (and its variants) with CVD or falls risk will require prospective studies. It is premature, based on the available cross-sectional data, to advocate for routine OH testing without such research. Second, the population from which the normative data was derived is homogeneous in race/ethnicity. The patterns of OH described here may not be relevant to populations with different dietary patterns, sodium intake, medication use, or with different CVD risk profiles. Third, it is important to distinguish ‘usual’ from ‘normal’ prevalence of OH. The data reported in this paper reflect a population with a high prevalence of hypertension and a high risk of vascular disease, i.e. usual rates. With efforts to promote cardiovascular health and prevent hypertension, rates of OH might fall and reflect ‘normal’ prevalence in a less diseased population. Fourth, the authors did not assess risk factors with OH (and its variants) and did not provide any information on how, when or what questions were used to assess OH symptoms during the testing. Fifth, the duration of the provocative test, 2 minutes, was less than the 3 minutes recommended by professional organizations. Lastly, the investigators used the Finometer. This device uses a finger BP cuff, with return flow calibration and height correction algorithms; it was judged to provide “reliable BP values” (with an estimated grade of A/B by British Hypertension Society Standards).17 However, independent testing of the Finometer as an accurate measure of BP by international standards is unavailable. Whether this device could be incorporated into routine care would also need to be assessed.

In conclusion, the authors document a high prevalence of age-associated OH in a representative sample of adults from Ireland. The continuous beat-to-beat monitoring provided by the Finometer device during the seated-to-standing change highlights the high prevalence of OH in the population, and in particular in the elderly. However, the clinical relevance of these findings must be established before routine testing in asymptomatic patients can be recommended.

Table 1.

Prevalence of Orthostatic Hypotension and variants of Hypotension in adults in the Irish Longitudinal Study on Ageing

Age in Years
50–59 60–69 70–79 >80
Orthostatic Hypotension (%)1 4.2 6.4 10.6 18.5
Initial orthostatic hypotension (%)2 35.0 31.1 32.4 29.8
Impaired blood pressure stabilization (%)3 9.1 14.3 25.7 41.2
1

Orthostatic Hypotension (OH)” was defined as a decrease in systolic BP of ≥20 mm Hg or diastolic BP of ≥10 mmHg at 2 minutes of standing

2

Initial orthostatic hypotension (IOH)” is defined as a drop in SBP ≥ 40 mmHg or DBP ≥20 mmHg within 15 seconds of standing accompanied by symptoms (e.g. dizziness or light-headedness)

3

Impaired blood pressure stabilization at 40 seconds” is defined by a lack of returning to baseline BP after 40 seconds

References

  • 1.Xin W, Lin Z, Mi S. Orthostatic hypotension and mortality risk: A meta-analysis of cohort studies. Heart. 2014;100(5):406–13. doi: 10.1136/heartjnl-2013-304121. [DOI] [PubMed] [Google Scholar]
  • 2.Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. doi: 10.1007/s10286-011-0119-5. [DOI] [PubMed] [Google Scholar]
  • 3.Wu JS, Yang YC, Lu FH, Wu CH, Chang CJ. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens Res. 2008;31(5):897–904. doi: 10.1291/hypres.31.897. [DOI] [PubMed] [Google Scholar]
  • 4.Finucane C, O’Connell M, Fan CW, et al. Age related normative changes in orthostatic blood pressure responses in a large population study: Findings from the Irish Longitudinal Study on Ageing (TILDA) Circulation. doi: 10.1161/CIRCULATIONAHA.114.009831. in press. [DOI] [PubMed] [Google Scholar]
  • 5.Gibbons CH, Freeman R. Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance. Neurology. 2006 Jul 11;67(1):28–32. doi: 10.1212/01.wnl.0000223828.28215.0b. [DOI] [PubMed] [Google Scholar]
  • 6.Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: Implications for management of cardiovascular disease. Am J Hypertens. 2011;24(2):135–44. doi: 10.1038/ajh.2010.146. [DOI] [PubMed] [Google Scholar]
  • 7.van Helden S, Wyers CE, Dagnelie PC, et al. Risk of falling in patients with a recent fracture. BMC Musculoskelet Disord. 2007;8:55. doi: 10.1186/1471-2474-8-55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: The maintenance of balance, independent living, intellect, and zest in the elderly of boston study. J Am Geriatr Soc. 2011;59(3):383–89. doi: 10.1111/j.1532-5415.2011.03317.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tinetti ME, Han L, McAvay GJ, et al. Anti-hypertensive medications and cardiovascular events in older adults with multiple chronic conditions. PLoS One. 2014;9(3):e90733. doi: 10.1371/journal.pone.0090733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8) JAMA. 2014;311(5):507–20. doi: 10.1001/jama.2013.284427. [DOI] [PubMed] [Google Scholar]
  • 11.Wright JT, Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499–503. doi: 10.7326/M13-2981. [DOI] [PubMed] [Google Scholar]
  • 12.Choulerton J, Mudd P, Mac Mahon M. Withdrawing antihypertensives on the basis of orthostatic hypotension. Age Ageing. 2010;39(4):518. doi: 10.1093/ageing/afq064. author reply 518. [DOI] [PubMed] [Google Scholar]
  • 13.Margolis KL, Palermo L, Vittinghoff E, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: The ACCORD trial. J Gen Intern Med. 2014 doi: 10.1007/s11606-014-2961-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Weir MR, Yeh F, Silverman A, et al. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: The SANDS trial. J Clin Hypertens (Greenwich) 2009;11(10):540–8. doi: 10.1111/j.1751-7176.2009.00121.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.SPS3 Study Group. Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet. 2013;382(9891):507–15. doi: 10.1016/S0140-6736(13)60852-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes. J Am Geriatr Soc. 2008;56(8):1409–16. doi: 10.1111/j.1532-5415.2008.01815.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Schutte AE, Huisman HW, van Rooyen JM, Malan NT, Schutte R. Validation of the finometer device for measurement of blood pressure in black women. J Hum Hypertens. 2004;18(2):79–84. doi: 10.1038/sj.jhh.1001639. [DOI] [PubMed] [Google Scholar]

RESOURCES